Press Releases

January 25, 2018
BOSTON , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,970,000 shares of its common stock
January 24, 2018
BOSTON , Jan. 24, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an underwritten public offering of its common stock.
January 19, 2018
— Elobixibat approved in Japan for the treatment of chronic constipation — — Albireo innovation leads to world’s first approved ileal bile acid transporter (IBAT) inhibitor — BOSTON , Jan. 19, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver
January 3, 2018
BOSTON, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that subsidiary Elobix AB has entered into an agreement with HealthCare Royalty Partners (HCR) to monetize its royalty rights under its license agreement with EA Pharma Co., Ltd.